BREA, Calif. (October 1, 2024) – Beckman Coulter,
Inc., has entered into a strategic alliance with Trillium
Diagnostics LLC, under the terms of which Beckman Coulter will
market specific products in North America and South America, and in
the majority of Europe, Asia and Australasia.
Trillium Diagnostics products covered in this agreement include
unique assays for feto-maternal hemorrhage testing (FETALtrol
control) and cellular HbF level quantitation (FMH QuikQuant), as
well as Leuko64, which is used for sepsis and infection detection
by flow cytometry.*
Adding these products to the Beckman Coulter line for flow
cytometry will enable the company to provide diagnostic
laboratories and research institutes with targeted flow cytometry
products that address specific unmet medical needs.
"Beckman Coulter is pleased to have Trillium Diagnostics as a
strategic partner and values their expertise," said Cynthia
Collins, group vice president of Cellular Analysis at Beckman
Coulter. "We are committed to being the leader in cellular
analysis and the addition of these three products to our portfolio
of cell sorters, flow cytometers and reagents will provide
customers with a broader selection of targeted flow cytometry
products."
"Trillium Diagnostics has been developing high quality flow
cytometry products that address unmet medical needs across the
globe for over 10 years," said Bruce Davis MD, president and
founder of Trillium Diagnostics. "We are confident that
Beckman Coulter's broad market reach, installed flow cytometer base
in clinical diagnostic laboratories, and extensive flow product
portfolio, coupled with our innovative flow cytometry products,
will further advance the field of cellular analysis and be of
mutual benefit to patients, laboratorians and both companies."
Trillium Diagnostics will continue to work with IQ Products, bv,
of The Netherlands, as manufacturer and their exclusive distributor
in the Benelux countries, with Beckman Coulter granted
co-exclusivity in all other global markets.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California,
develops, manufactures and markets products that simplify, automate
and innovate complex biomedical tests. This year marks the
company's 75th anniversary of advancing healthcare. More than
200,000 Beckman Coulter systems operate in laboratories around the
world, supplying critical information for improving patient health
and reducing the cost of care. Recurring revenue, consisting of
consumable supplies (including reagent test kits), service and
operating-type lease payments, represents about 80 percent of the
company's 2009 revenue of $3.3 billion. For more information, visit
www.beckmancoulter.com or
www.beckmancoulter.com/75years.
About Trillium Diagnostics LLC.
Trillium Diagnostics LLC, based in Bangor Maine, develops,
manufactures and markets niche flow cytometry products that address
unmet medical needs. Based on a foundation of recognized expertise
in laboratory hematology and flow cytometry, Trillium Diagnostics
is dedicated to improving healthcare outcomes by providing niche
flow cytometry products that are innovative, robust and reliable.
For more information visit www.trilliumdx.com.
Beckman Coulter and the stylized logo are registered trademarks
of Beckman Coulter, Inc.
*FETALtrol, FMH QuikQuant and Leuko64 are registered trademarks of
Trillium Diagnostics. Currently FMH QuikQuant and Leuko64 are
marketed as RUO in the U.S. and have not yet been cleared as an IVD
by the U.S. FDA.
SOURCE